Genmab A/S has reported that net sales of DARZALEX® (daratumumab) reached USD 3.539 billion in the second quarter of 2025. The sales were divided between USD 2.017 billion from the United States and USD 1.521 billion from the rest of the world. These figures represent the worldwide net trade sales of DARZALEX, including the subcutaneous version sold as DARZALEX FASPRO® in the U.S. Genmab receives royalties from these sales under an exclusive worldwide license agreement with Johnson & Johnson for the development, manufacturing, and commercialization of daratumumab. No additional information on net income, profit, or earnings per share was provided in the announcement, nor was there any outlook or guidance included.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001118187-en) on July 16, 2025, and is solely responsible for the information contained therein.